Date: 2011-09-22
Type of information: R&D agreement
Compound: small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases
Company: Almirall (Spain) Proteros biostructures (Germany)
Therapeutic area: Inflammatory diseases
Type agreement: R&D
Action mechanism:
Disease: inflammatory diseases
Details: Almirall. and Proteros biostructures GmbH today announced they have entered into a research collaboration to identify small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases. Under the agreement Proteros will apply its protein structure-based drug discovery platform. Proprietary site specific screening technologies, novel fragment libraries and structural biology will be deployed to support medicinal chemistry objectives of the program, to identify and optimize for selectivity and potency small molecule inhibitors of a specific enzyme.
Financial terms:
Latest news:
